跳转至内容
Merck
CN

MAB8537

Anti-Herpes Virus 6 Antibody, A & B, gp 60/110

Chemicon®, from mouse

别名:

HHV6

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Anti-Herpes Virus 6 Antibody, A & B, gp 60/110, Chemicon®, from mouse

biological source

mouse

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunofluorescence: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG2b

shipped in

wet ice

Quality Level

Application

Detect Herpes Virus 6 using this Anti-Herpes Virus 6 Antibody, A & B, gp 60/110 validated for use in IF, IP & WB.
Western Blot 1:10 - 1:50

Immunofluorescence 1:10-1:50

Immunoprecipitation 1:10-1:50

Optimal working dilutions must be determined by end user.

Biochem/physiol Actions

Specific for the gp 60/110 envelope glycoprotein of HHV6.

CELLULAR LOCALIZATION:

Cytoplasmic and membrane

STRAIN RECOGNITION:

Types A & B

Immunogen

Epitope: A & B, gp 60/110

Physical form

Format: Purified
Purified immunoglobulin. Liquid in 0.01 M phosphate buffered saline (PBS) pH 7.2, containing 0.1% sodium azide.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications.
J O Virtanen, M Farkkila, J Multanen, L Uotila, A J Jaaskelainen, A Vaheri, M Koskiniemi
Journal of Neurovirology null
Purification of infectious human herpesvirus 6A virions and association of host cell proteins.
Hammarstedt, M; Ahlqvist, J; Jacobson, S; Garoff, H; Fogdell-Hahn, A
Virology Journal null
Kageaki Kuribayashi et al.
Internal medicine (Tokyo, Japan), 45(7), 475-478 (2006-05-09)
A 31-year-old man referred to our hospital for treatment of his chronic myeloid leukemia (CML) in the first chronic phase by bone marrow transplantation. We pretreated him with cyclophosphamide and total body irradiation and bone marrow transplantation (BMT) was carried

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持